Regulatory, Security Concerns Force Wuxi NextCODE To Cut China Ties
China Operations Face Potential Overhaul
Executive Summary
As China tightens its grip over clinical research using human genetic data in the country, and the US increases scrutiny over the use of personal data, multinational drug developers may face a difficult choice or even create separate entities to cater to local regulatory requirements. WuXi NextCODE provides one interesting case study.
You may also be interested in...
3D Med, Alphamab Get First SubQ Immuno-Oncology Approval, In China
A landmark approval and domestic tie-up in China mark the fast innovation that is shaping the country’s health sector.
Pharma Will Need To Embrace More Inward-Looking China
The world’s second-largest economy is fast moving away from reforms and open to a "dual circulation" model, focusing on domestic market consumption while reducing export-driven production. Executives and investors shared views at a conference on whether multinational pharma firms are still welcome in China and what opportunities may lie in the drastic policy shift.
Pharma Will Need To Embrace More Inward-Looking China
The world’s second-largest economy is fast moving away from reforms and open to a "dual circulation" model, focusing on domestic market consumption while reducing export-driven production. Executives and investors shared views at a conference on whether multinational pharma firms are still welcome in China and what opportunities may lie in the drastic policy shift.